Immuron Posts 16% Q3 Sales Growth as Travelan Gains Traction in Three Markets
Immuron delivers double-digit Q3 sales growth as Travelan gains traction across key markets
Immuron has reported Q3 global sales of AUD$1.5 million, up 16% on the prior comparative period, as its flagship product Travelan continues to build commercial momentum across Australia, Canada, and the United States. Year-to-date global sales reached AUD$5.7 million, up 7% on the prior comparative period, demonstrating sustained growth for the ASX and NASDAQ-listed biopharmaceutical company’s over-the-counter immune supplement.
When big ASX news breaks, our subscribers know first
Regional performance breakdown
The Q3 sales update provides investors with visibility on where growth is materialising and which markets are driving the company’s commercial trajectory.
Australia remains the growth engine
Australia delivered Q3 sales of AUD$0.9 million, up 15% on the prior comparative period, with year-to-date sales reaching AUD$4.2 million, up 14% on the prior comparative period. The domestic market contributes the majority of Immuron’s global revenue, and growth has been attributed to several factors: increased awareness driven by digital and social media marketing, same-store growth from expanded in-store promotion, new store ranging secured during FY25, and increased Southeast Asian travel by Australian consumers.
Canada sales surge following retail expansion
Canadian Q3 sales reached AUD$0.1 million, up more than 100% on the prior comparative period and 82% on the prior quarter. The sequential growth follows initial sales to Jean Coutu, the leading pharmacy group in Quebec, Canada’s second-largest province by population. During Q1 FY25, the company completed a pipeline fill across more than 1,000 retail doors within key pharmacy and grocery groups, with consumer pull-through now materialising as in-store educational programmes, promotions, and social media marketing build brand awareness. Year-to-date sales are down 65% on the prior comparative period due to the timing of last year’s pipeline fill, but the sequential quarterly trajectory is the key metric for investors tracking Canadian market penetration.
US holds steady despite currency headwinds
US Q3 sales came in at AUD$0.5 million, up 1% on the prior comparative period, with year-to-date sales reaching AUD$1.3 million, up 10% on the prior comparative period. The company cited several marketing initiatives, including an improved Travelan store on Amazon.com, dedicated US-focused Facebook and Instagram pages, and increased paid social, influencer, and organic social media marketing. Growth was partially offset by the strengthening Australian dollar against the US dollar, which reduced the AUD-equivalent value of US sales.
| Region | Q3 Sales (AUD) | Q3 % Change | YTD Sales (AUD) | YTD % Change |
|---|---|---|---|---|
| Australia | $0.9M | +15% | $4.2M | +14% |
| Canada | $0.1M | >100% | $0.1M | -65% |
| USA | $0.5M | +1% | $1.3M | +10% |
| Global | $1.5M | +16% | $5.7M | +7% |
What is Travelan and why does it matter?
Travelan is an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal tract. The product uses hyper-immune bovine antibodies derived from engineered colostrum, which when taken with meals bind to diarrhea-causing bacteria to prevent colonisation and associated digestive tract disorders. In Australia, Travelan is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of traveller’s diarrhea and minor gastrointestinal disorders. In Canada, it holds licensed natural health product status (NPN 80046016) with similar indications, whilst in the United States it is sold as a dietary supplement for digestive tract protection.
Travelan represents Immuron’s near-term revenue generator whilst the company develops its broader polyclonal antibody platform. Growing sales across multiple geographies demonstrate market acceptance and validate the commercial thesis underpinning the company’s dual ASX and NASDAQ listing.
Marketing strategy driving awareness and repeat purchases
Management’s approach centres on building brand awareness to convert trial customers into repeat purchasers, with marketing initiatives tailored to each region:
- Australia: Extensive digital and social media marketing to drive awareness and consideration, supported by in-store promotions to encourage trial and repeat purchase
- Canada: In-store educational programmes and promotional activities to build pull-through from the 1,000+ retail doors established during FY25, supplemented by social media marketing
- USA: Optimised Amazon store presence, dedicated local social media pages (Facebook and Instagram), and increased paid social and influencer marketing to reach target demographics
Same-store growth in Australia suggests the strategy is generating both new customer acquisition and repeat purchases, a critical metric for assessing the sustainability of revenue growth in Immuron’s largest market.
The next major ASX story will hit our subscribers first
What to watch next
With Q3 marking the final quarter before Q4 FY26, investors will look for continued momentum across all three regions to deliver a full-year result that demonstrates sustainable commercial traction. Canada presents a particularly important market to watch, given the Jean Coutu relationship and the 82% sequential quarterly growth trajectory. Travel seasonality, with northern hemisphere summer approaching, could support US and Canada sales in coming quarters as consumers increase international travel. The company’s dual listing on both ASX and NASDAQ provides investors with exposure across two markets, with the Q3 results suggesting Travelan’s commercial viability is strengthening as marketing investment converts to revenue growth.
Want to Track Immuron’s Growth Trajectory as Travelan Expands Globally?
With Q3 sales up 16% and sequential quarterly growth accelerating in Canada following retail expansion, Immuron’s commercial strategy is delivering measurable results across three key markets. The company’s flagship product continues to demonstrate strong consumer pull-through as marketing investment converts to revenue growth.
To access quarterly reports, product updates, and detailed market expansion announcements, visit the Immuron investor centre for comprehensive company information. Stay informed on how management is executing its multi-regional growth strategy and building Travelan into a sustainable revenue generator.